icon-cookie
The website uses cookies to optimize your user experience. Using this website grants us the permission to collect certain information essential to the provision of our services to you, but you may change the cookie settings within your browser any time you wish. Learn more
I agree
blank_error__heading
blank_error__body
Text direction?

Humidified High Flow Nasal Cannula Supportive Therapy Improves Outcomes in Lung Transplant Recipients Readmitted to the Intensive Care Unit Because of Acute Respiratory Failure

Transplantation. 99(5):1092–1098, MAY 2015

DOI: 10.1097/TP.0000000000000460

,  

PMID: 25340596

Issn Print: 0041-1337

Publication Date: 2015/05/01

Humidified High Flow Nasal Cannula Supportive Therapy Improves Outcomes in Lung Transplant Recipients Readmitted to the Intensive Care Unit Because of Acute Respiratory Failure

Oriol Roca; Marina García de Acilu; Berta Caralt; Judit Sacanell; Joan R. Masclans

+ Author Information

Abstract

Background

The effectiveness of humidified high flow nasal cannula (HFNC) in lung transplant (LTx) recipients readmitted to intensive care unit (ICU) because of acute respiratory failure (ARF) has not been determined to date.

Methods

Retrospective analysis of a prospectively assessed cohort of LTx patients who were readmitted to ICU because of ARF over a 5-year period. Patients received conventional oxygen therapy (COT) or HFNC (Optiflow, Fisher & Paykel, New Zealand) supportive therapy according to the attending physician’s criteria. Treatment failure was defined as the need for subsequent mechanical ventilation (MV).

Results

Thirty-seven LTx recipients required ICU readmission, with a total of 40 episodes (18 COT vs. 22 HFNC). At ICU admission, no differences in comorbidities, pulmonary function, or median sequential organ failure assessment (COT, 4 [interquartile range, 4–6] vs. HFNC, 4 [interquartile range, 4–7]; P = 0.51) were observed. Relative risk of MV in patients with COT was 1.50 (95% confidence interval [95% CI], 1.02–2.21). The absolute risk reduction for MV with HFNC was 29.8%, and the number of patients needed to treat to prevent one intubation with HFNC was 3. Multivariate analysis showed that HFNC therapy was the only variable at ICU admission associated with a decreased risk of MV (odds ratio, 0.11 [95% CI, 0.02–0.69]; P = 0.02). Moreover, nonventilated patients had an increased survival rate (20.7% vs. 100%; relative rate 4.83 [95% CI, 2.37–9.86]; P Conclusion

HFNC O2 therapy is feasible and safe and may decrease the need for MV in LTx recipients readmitted to the ICU because of ARF.

Measure
Measure
Related Notes
Get a free MyMarkup account to save this article and view it later on any device.
Create account

End User License Agreement

Summary | 0 Annotations